We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 28

EU adds pharmaceuticals to water pollution watch list

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety

EU Court of Justice nixes patents for stem-cell inventions involving human embryo destruction

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 20 2011

The European Union (EU) Court of Justice has determined that EU patent law does not protect neural precursor cells and the processes for their production from embryonic stem cells

Researchers protest ECJ advocate general’s position on patenting stem cell technologies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 5 2011

Viewing the issue as a matter of morality, the advocate general of the European Court of Justice (ECJ) recently delivered a non-binding ruling that would render unpatentable the cells removed from the human embryo at the blastocyst stage, because the removal involves the embryo's destruction

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

EU agency will reinstate Ranbaxy’s GMP certificate

  • Shook Hardy & Bacon LLP
  • -
  • European Union, India
  • -
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."

European nations sign MOU to manage life-science information

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • September 22 2011

Denmark, Finland, the Netherlands, Sweden, and the United Kingdom have reportedly signed a memorandum of understanding (MOU) with the European Molecular Biology Laboratory to create an infrastructure that would both manage and safeguard life-science data generated by publicly funded research

EU Medicines Agency plans to appeal interim rulings on release of clinical trial data

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European

EU medical device manufacturers address plan to change regulatory directives

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • February 8 2013

Eucomed, an organization that represents the interests of the European medical device industry, has issued a position paper that assesses a number of

EU trade group issues voluntary code for disclosures by pharma companies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has issued a "Code on Disclosure of Transfers of Value from